The Anti-Ischemic Mechanism of Action of Ranolazine in Stable Ischemic Heart Disease
- 1 September 2010
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 56 (12), 934-942
- https://doi.org/10.1016/j.jacc.2010.04.042
Abstract
No abstract availableKeywords
Funding Information
- CV Therapeutics, Inc
- CV Therapeutics
This publication has 26 references indexed in Scilit:
- Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical TrialsDrug Information Journal, 2008
- Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation Acute Coronary SyndromesThe MERLIN-TIMI 36 Randomized TrialJAMA, 2007
- Antianginal Efficacy of Ranolazine When Added to Treatment With AmlodipineJournal of the American College of Cardiology, 2006
- The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunctionEuropean Heart Journal Supplements, 2006
- Chronic Stable AnginaNew England Journal of Medicine, 2005
- Comparative efficacy of ranolazine versus atenolol for chronic angina pectorisThe American Journal of Cardiology, 2005
- Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe anginaJournal of the American College of Cardiology, 2004
- Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic AnginaA Randomized Controlled TrialJAMA, 2004
- A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agentsThe American Journal of Cardiology, 1999
- Application of computerized exercise ECG digitizationJournal of Electrocardiology, 1992